Austrian Exhibitors at BIO-Europe 2013
56
BIO Europe 2013 Austrian Exhibitors
-
Upload
sonja-polan -
Category
Documents
-
view
271 -
download
7
description
Read up on all the Austrian participants at this key event for the global biotech industry - to be held in Vienna in 2013
Transcript of Austrian Exhibitors at BIO-Europe 2013
BIOEurope 2013Austrian Exhibitors
BIO-Europe 2013November 4 – 6Vienna, AustriaWelcome to Vienna! We are very proud to host BIO-Europe, the world’s largest stand-alone partnering event for a second time after 2009. The 19th annual edition of BIO-Europe, will gather leaders of the life science industry at the Wiener Messe to take biotech dealmaking to a new level.
Austria prides itself on a long tradition of revolutionary discoveries in the life sciences, with such famous names as Theodor Billroth, Karl Landsteiner and Max Perutz. But today, too, or perhaps especially today, Austria has a wealth of innovative potential to offer.
A thriving environment of successful and innovative companies has put Austria fi rmly on the European life science map. The combination of global players with research facilities in Austria and young, dynamic start-ups in close cooperation with excellent universities creates an ideal environment for the development, growth and prosperity of the Austrian life science industry.
The following pages will give you a brief overview about the Austrian companies and re-search organisations participating at BIO-Europe. 102 of the most innovative Austrian bio-tech companies and research organisations as well as Austrian regional cluster organisation will present their products and services to the international biotech scene.
We hope you will enjoy your stay in Vienna, thanks to its grand historic buildings as well as its cutting-edge biotech technologies. Don’t miss the opportunity to get to know better the Aus-trian burgeoning life sciences industry and its innovative companies at our Austrian pavilion.
See you there!
Mag.a Edeltraud StiftingerManaging Director Austria Wirtschaftsservice GesmbH
Life Science Austria PavilionBIO-Europe, Booth 46See you there! www.lifescienceaustria.at
01
Life Science Austria: Advancing life science at the heart of EuropeIn recent decades, a lively scene of innovative biotechnology companies has put Austria on the European life science map. With their excellent skilled staff and their broad technical and scien-tific expertise, these companies can play a pivo-tal role in developing the medicine of the future. In 2012 Austrian 288 biotechnology and pharma companies made more than 10 billion euros in turnover. These companies – from the micro-busi-ness with two or three employees to the large-scale enterprise with thousands of staff – employ more than 25,000 people.
Life Science Austria (LISA) promotes the life science sector in Austria on the international stage and is the first point of call for enquiries relating to it. We
are committed to the development, growth and prosperity of the Austrian life science industries as a leading component of the Austrian economy.
In the home market, LISA is a resource for all life science companies within and all compa-nies wishing to relocate to Austria. We see our role in helping companies make connections lo-cally and further afield. We also play a big part in helping new companies get started through our PreSeed – € 200.000 non-refundable – and Seedfinancing – € 1 Mio, refundable when pro-fitable – funding programmes. Every two years, we run a life science business plan competition BOB – Best of Biotech as our way of fostering a culture of excellence.
02
On the international front, LISA also works to-wards Austria being a country known worldwide for the excellence of its life science sector. We maintain a regular and high profile presence at leading international life science conferences and exhibitions.
Organised through the regional life science clus-ters, LISA represents companies in the therapeu-tic, medical technology and diagnostic sectors as well as providers of enabling technologies and re-lated service companies located in the following regional clusters:
• ecoplus (Lower Austria)• Health Technology Cluster (Upper Austria)• Human Technology Styria (Styria)• LISAvienna (Vienna)• Standortagentur Tirol/Cluster Life Sciences (Tyrol)
Let us know if you want to hear more or have an interest in speaking to a life science business in Austria.
LISA is run by Austria Wirtschaftsservice GesmbH (aws) on behalf of the Federal Ministry of Econo-my, Family and Youth.
03
For more information on LIFE SCIENCE AUSTRIA contact:Sonja [email protected]+43 1 501 75 510www.lifescienceaustria.at
ABF Pharmaceutical Services GmbHBooth 46
ACIB GmbHBooth 46
Altmannsdorfer Str 104A-1120 ViennaT. +43 (0)1 890 120033M. +43 (0)676 897 115 533F. +43 (0)1 890 120 [email protected]
Petersgasse 14A-8010 Graz
T. +43 (0)1 476 548 043F. +43 (0)1 476 548 039
04
ABF Pharmaceutical Services – a medium sized global specialist CMO/Central Lab offering label-ling, packaging, QP release and distribution of pharma/bio pro-ducts. Focused services include everything required for getting IMPs to the patient, drug storage across all temperature ranges and
Central Lab services. Renowned for delivering high quality, clients see us as “the right size” CMO/Central Lab - big enough to suc-cessfully manage your large global trial project, but with a persona-lized flexible service level associa-ted with a smaller nimble organi-zation. Simplify it with ABF!
The Austrian Centre of Industrial Biotechnology (acib) is a K2 non-profit research center based in the cities of Vienna, Graz and Inns-bruck. ACIB is a competent part-ner for research to apply biotech-nology in industrial production, focused on biocatalysis, enzymes and (pharmaceutical) protein pro-
duction and purification.acib’s ambitious research pro-gramme includes development of new microbial and mammalian expression systems and concepts, extended innovative applications of biocatalysis, and understanding bioproduction on a molecular and genome wide basis.
Contact personDr. Erich Wirtz, Ph.D.
Contact personDr. Concetta Giuliani,Research Manager
Activartis Biotech GmbH
Booth 46
AFFiRiS AGBooth 39
Zimmermannplatz 10A-1090 Vienna
T. +43 (0)1 40170 4080F. +43 (0)1 40170 64080
05
AFFiRiS is an innovative, Vienna based biotechnology company. Using its proprietary AFFITOME® technology, it develops custo-mized peptide-based vaccines, so called AFFITOPES®, to target chro-nic diseases with attractive mar-kets and unmet medical needs.
Indications include Alzheimer’s disease, Parkinson’s disease, Athe-rosclerosis, Diabetes and several others. AFFITOPES® mimic the structure of particular natural ep-itopes in disease targets and are capable of evoking therapeutic antibody responses.
Activartis develops a dendritic cell-based cancer immune therapy, AV0113. It is individually tailored for each patient’s tumour and is, therefore, in principle applicable for any type of cancer. In a rando-mised clinical trial for the treat-
ment of brain cancer, significant-ly improved one-year survival is found as an early trend for efficacy. Activartis seeks a partnership with a pharmaceutical company for late stage clinical development and worldwide market introduction.
Karl-Farkas-Gasse 22A-1030 ViennaT. +43 (0)1 798 15 75 300F. +43 (0)1 798 15 75 [email protected]
Contact personThomas Felzmann, CEO
Contact personJulia Bock,
Communications
AIT Austrian Institute of TechnologyBooth 46Donau-City-Straße 1A-1220 ViennaT. +43 (0)1 50550 [email protected] www.ait.ac.at
06
The AIT Austrian Institute of Tech-nology is Austria‘s largest non-university research institute with over 1,100 employees. The AIT Health & Environment Depart-ment offers expertise in saliva diagnostics: Identification and validation of DNA-methylation and auto-antibody biomarkers,
Technologies to standardize saliva sampling and handling, Bioinfor-matics for App based data analysis and new workflows, Diagnostic Biosensors using optical, mag-netical and nanomaterial-based technologies and Integration of building blocks for saliva-based Point-of-Care devices.
Akron Molecules is a clinical stage biopharmaceutical company de-dicated to the discovery and de-velopment of novel therapeutics, based on a “drug repurposing“ approach, for the treatment of hu-man diseases with unmet medical need, with a current focus on chro-nic pain. Akron is currently seeking to raise EUR 7 million in a series B
financing round. Akron’s lead drug candidate, AKR 202, is scheduled to enter a phase II study in pain associated with osteoarthritis in Q4’13 with top-line data expected in Q1’ 15. AKR 202 is a once daily oral product with a favourable sa-fety profile compared to currently approved analgesics.
Contact personDr. Martin Weber
Contact personDr. Henrik Nilsson, CEO
Akron Molecules GmbH
Booth 46Helmut-Qualtinger-Gasse 2
A-1030 ViennaT. +43 (0)1 2360429
Anagnostics Bioanalysis GmbH
Booth 46Westbahnstraße 55A-4300 St. Valentin
T. +43 (0)7435 58193 0F. +43 (0)7435 58193 [email protected]
07
Apeiron is a primarily privately fi-nanced biotech company in Vien-na, developing immunologic and biologic therapies against cancer. Its portfolio consists of five clinical projects and some preclinical ap-proaches. In addition to the lead project APN311 Apeiron develops further clinical projects. APN301 is an immunocytokine and cur-
rently in a phase II in the US and Canada against neuroblastoma (relapsed/refractory patients) and in a separate trial against me-lanoma. The recombinant human Angiotensin Converting Enzyme 2 (GSK2586881) was licensed to Gla-xoSmithKline in 2010 and is explo-red in an phase II study in ARDS.
Anagnostics develops systems and tests for multiplex clinical diagnostics especially in the fol-lowing fields:• Inflammation monitoring (integra-ted sepsis diagnostics): comprehen-sive and fast evaluation of inflam-mation status out of whole blood • detection of pathogens (integ-
rated sepsis diagnostics): compre-hensive, fast and sensitive detec-tion of bacteria and fungi • companion diagnostics: cost effici-ent, sensitive and specific detection of mutations in KRAS, BRAF and EGFR • drugs of abuse screening: com-prehensive, fast and simple out of urine, serum and saliva.
Contact personMag. Christoph Reschreiter, CEO
Contact personMag. Lukas Kadawy, CFO
APEIRON Biologics AGBooth 46Campus Vienna Biocenter 5A-1030 ViennaT. +43 (0)1 865 65 77F. +43 (0)1 865 65 77 [email protected]
Mariahilferstr. 136, Top 1.15A-1150 ViennaT. +43 (0)664 143 29 19 F. +43 (0)1 2533 033 77 [email protected] www.apeptico.com
08
APEPTICO is a privately-held bio-technology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases of the lung. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biophar-
maceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids gene-ral risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASETM and PEPSCREENTM to significantly reduce cost and to shorten time to market.
Contact personBernhard Fischer, CEO
Arsanis Biosciences GmbH
Booth 46Helmut-Qualtinger-Gasse 2. 1/3. Stock
A-1030 ViennaT. +43 (0)1 7990117
F. +43 (0)1 7990117 [email protected]
www.arsanis.com
Arsanis Biosciences is a biotech-nology company dedicated to the development of human antibody based therapeutics against severe infectious diseases.Arsanis is developing a pipeline of monoclonal antibody programs targeting infectious diseases where current approaches are eit-her ineffective or non-existent.
Our’ lead program, ASN-100, a monoclonal antibody cocktail to prevent and treat severe hospital associated Staphylococcus aureus infections, is in preclinical deve-lopment.Since its founding in 2010, Arsa-nis has emerged as a leader in the field of antibody based anti-infectives.
Contact personSophie Zettl, PhD, Head of Business Development
APEPTICO Forschung und EntwicklungBooth 46
Assign Group
Booth 46Donau-City Strasse 6
A-1220 ViennaT. +43 (0)1 4103 38 05
F. +43 (0)1 4103 38 05 [email protected]
09
Assign is Austria’s largest clinical development organisation. With a reputation for excellence in complex trials, ASSIGN has accu-mulated expertise through >350 studies, with an emphasis on the therapeutic areas of oncology, vaccines, personalised medicine and orphan diseases. Our experi-ence will help you save valuable
time and budget, allowing you to focus on what you do best.Known as the “right-size” CRO, Assign strikes the perfect balance between its 10+ years of experi-ence & strong Eastern and Wes-tern European presence with fle-xibility & responsiveness, thereby delivering quality and efficiency to your trials.
Contact personAnusha Subramaniam, Business Development Manager
aws – Austria Wirtschaftsservice GmbHBooth 46
aws is Austria’s national state-owned promotional bank. As a one-stop-shop for business it is set to realize the key objectives of the Austrian government’s eco-nomic policies. aws initiatives to support Austrian companies in-clude guarantees and loans. aws is engaged in technology transfer activities, and supports the esta-
blishment and development of high-tech companies. Focusing on start-up ideas in biotechnology and medical devices, aws provides financial support through two fun-ding programmes: LISA PreSeed (€ 200,000) and LISA Seedfinan-cing (€ 1 million). More information: www.lifescienceaustria.com; www.preseed.at; www.seedfinancing.at
Walcherstraße 11 AA-1020 ViennaT. +43 (0)1 501 75 0F. +43 (0)1 501 75 [email protected]
Contact personArnold Reikerstorfer,
Angela Siegling
Baxter Innovations GmbHBooth 46Industriestraße 67A-1220 Vienna T. +43 (0)1 20100 247 3006E-Mail: [email protected]
10
Baxter is Austria‘s largest R&D driven biotech and pharma com-pany. At the same time, Austria is Baxter‘s most important research location for its largest and most R&D intensive department: 80 percent of the product portfolio of the BioScience division are deve-loped and or manufactured here.
In Vienna, Baxter runs one of the biggest and most efficient plasma fractionation facilities worldwide. It is able to process some 2.3 mil-lion liters plasma per year into 18 substances that feed into a broad range of pharmaceuticals of ur-gent need.
Contact personNadja Spence-Simkovsky
BDS Pharma GmbH
Booth 46Marburger Kai 47
A-8010 GrazT. +43 (0)664 356 03 89
[email protected] www.bds-pharma.at (in construction)
BDS Pharma GmbH is a drug deli-very company. The Company’s mis-sion is to develop and commercia-lize a novel drug delivery platform combining the use of conventional polymer drug delivery vehicles and approved drugs to be implanted di-rectly within the Central Nervous System. The polymeric delivery de-vices can provide release of appro-
priate doses of drugs for the given clinical population within the focal site in the brain without causing systemic side effects. Our lead pro-duct “Nicaplant” (patent pending) is a brain implant designed to pre-vent and treat cerebral vasospasm following aneurismal subarachno-id haemorrhage (aSAH) and other brain injuries.
Contact personBernd Pöcheim, CEO
BDSPHARMA
BIA SeparationsGmbH
Booth 46Europastrasse 8
A-9524 VillachT. +386 (59) 699 500
[email protected] www.biaseparations.com
11
BIA Separations manufactures a new generation of proprietary se-paration (purification) columns that boost productivity and provide cost efficiency in the purification of large biopharmaceuticals. The Convective Interaction Media (CIM®) technolo-gy enables the purification of large proteins, plasmid DNA, phages, viral
vaccines and vectors and other large molecules. The technology is fully scalable allowing, to support the se-paration and purification activities in laboratory based research, QC/QA process controls and industrial scale manufacturing. BIA Separations is also offering Platform industrial pu-rification processes.
Contact personAles Strancar, CEO
Biobank GrazBooth 46
The Biobank Graz collects various biospecimens and associated data of Styrian probands to support medical research. Samples from selected patients at the University Hospital of Graz, who have signed an informed consent, are stored in different ways for different ap-proaches. This collection contains
body fluids like serum (-80°C), formalin fixed paraffin embedded samples as well as cryopreserved tissue samples. This non-profit organisation presents an active scientific partner and supports customers’ by clinical expertise, technology for analyses and orga-nisation.
Stiftingtalstrasse 3.1A-8010 GrazT. +43 (0)316 38572716F. +43 (0)316 [email protected]/biobank
Contact personKarine Sargsyan,
Leader of Biobank Graz
BIOCRATES Life Sciences AGBooth 46Eduard-Bodem-Gasse 8A-6020 InnsbruckT. +43 (0)512 579823F. +43 (0)512 579823 [email protected]
12
BIOCRATES Life Sciences AG of-fers unique solutions for targe-ted, quantitative and quality con-trolled Metabolic Phenotyping (“Deep Phenotyping”). Our mass spectrometry based assays deli-ver unprecedented accuracy and precision for a comprehensive and predictive understanding of phe-
notypes and metabolic pathways. Our metabolomics solutions set a new level for standardized data processing, exchange and storage that can readily meet the rigorous demands of various disciplines such as life sciences, personalized medicine, clinical research, and drug development.
Contact personDr. Wulf Fischer-Knuppertz, CEO
Biomay AGBooth 32
Vienna Competence CenterLazarettgasse 19/1
A-1090 ViennaT. +43 (0)1 7966 296 100F. +43 (0)1 7966 296 222
Biomay is a leader in the discove-ry and development of innovative immunotherapeutics against aller-gies. Our vaccines are derived from the IgE binding domains of aller-gens, linked to a highly immunoge-nic carrier protein. By design, these vaccines lack both IgE dependent early phase and T-cell dependent late phase adverse reaction. The
lead product BM32, a tetravalent grass pollen allergy vaccine, is cur-rently tested in a phase IIb clinical trial. Uniquely, we manufacture our own API in our propriatery GMP-approved plant. We offer ex-cess capacity as a contract manu-facturer. Finally, we derive revenue from the sale of research grade re-combinant allergens.
Contact personDr. Rainer Henning, CEO
Biomedica Medizinprodukte GmbH & Co KG
Booth 46Divischgasse 4A-1210 Vienna
T. +43 (0)1 291 07 56F. +43 (0)1 290 14 29
13
Biomedica is a leading distribution partner for high value medical pro-ducts and in vitro diagnostics in the human and veterinary field as well as products for life sciences with subsidiaries in all 13 CEE countries and a team of 250 professionals. Additionally, Biomedica provides innovation in the following areas:
• Biomedica Immunoassays: highly sensitive Elisa test kits for clinical research;• DCX: Surface and room disinfection in hospitals via a dry hydrogenperoxide aersol;• PhC Autoinjectors for intra- muscular emergency injection for military and civil use.
Contact personBernhard Küenburg, Managing Director
BIRD-C GmbH & Co KGBooth 46
BIRD-C is commercializing a pro-prietary technology platform en-tailing empty, non-living bacterial particles generated from Gram- bacteria (Bacterial Ghosts – BGs) via an innovative, genetically in-duced, lytic inactivation process. Utilizing this platform technology BIRD-C is developing:
• A portfolio of veterinary vaccines licensed to a major US veterinary pharmaceutical company in January 2012;• An innovative treatment for inflammatory bowel disease in collaboration with a German pharmaceutical company;• A novel melanoma vaccine based on genetically modified BGs.
Hauptstrasse 88A-3420 KritzendorfT. +43 (0)699 1 47654 19 F. +43 (0)2243 [email protected] www.bird-c.com
Contact personAlexander Matis, MSc, MBA
Business Development
Boehringer Ingelheim Biopharmaceuticals GmbHBooth 36Binger Straße 173D-55216 Ingelheim am RheinT. +49 (6132) 77 90506F. +49 (6132) 77 98287pauline_eva.bronzel@boehringer-ingelheim.comwww.bioxcellence.com
14
As a leading biopharmaceutical contract manufacturer Boehringer Ingelheim BioXcellenceTM offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production
technology chain from DNA to fill and finish under one roof at its fa-cilities in Biberach (Germany), Vi-enna (Austria), Fremont (USA) and Shanghai (China).Boehringer Ingelheim BioXcel-lenceTM makes outsourcing easy.
Contact personPauline Bronzel,
Marketing Management
BOKU – University of Natural Resources and Life Sciences
Booth 45Gregor Mendel Straße 33
A-1180 ViennaT.+43 (0)1 47654 1015
F. +43 (0)1 47654 [email protected]
www.boku.ac.at
As a university of life sciences, BOKU assumes important social and political responsibilities. Its core competency is the research and communication of ways of sustainable use and the protection of natural resources. The inter-disciplinary approach in research
results in numerous rewarding inventions and publications espe-cially in the field of Biotech and Agrobiotech. Moreover in recent years, several successful spin-offs were founded at BOKU, especially in the Bio-Science enviroment (e.g. Polymun, f-star, Evercyte)
Contact personBernhard Koch,Techtransfermanager
Campus Science Support Facilities, CSF Vienna
Booth 45Dr. Bohr-Gasse 3
A-1030 ViennaT. +43 (0)664 808477030
15
The CSF NGS facility is Austria‘s most experienced next genera-tion sequencing provider using Illumina‘s HiSeq systems to deliver outstanding throughput and ser-vice quality. Services include the preparation of libraries, sequen-cing of samples deriving from a
variety of applications and bioin-formatic support.The CSF Bioinformatics and Scien-tific Computing facility (BioComp) provides unique expertise and ser-vices in the areas of bioinformatics and scientific computing to acade-mic and industrial researchers.
Contact personAndreas Sommer,Head of NGS Facility
CBC Capricorn Biotech Consulting e.U.Booth 46
CBC Capricorn Biotech Consulting provides services in the field of busi-ness development, strategic part-nering, commercial operations and funding for small to medium sized firms in the life science sector. This could be biotech firms with a focus on, but not limited to, vaccines and antibodies as well as diagnostic or medical device companies.
Foci for the attendance of the present Bio-Europe are:• Novel Vaccine Adjuvant and Delivery Platform: Strategic Partnering for ViscoGel, Sweden;• Novel Cancer Biomarker CA IX: Market Exploration for BioScience, Slovakia; • Present the services of CBC to potential clients.
Untere Weißgerberstraße 49/19A-1030 ViennaT. +43 (0)676 930 3370martin.goetting@cbcmg.comwww.capricorn-biotech-consulting.com
Contact personMartin Götting,
General Manager
AKH BT 25.3Lazarettgasse 14A-1090 ViennaT. +43 (0)1 40160 70011F. +43 (0)1 40160 970 [email protected]
16
CeMM is an international, inde-pendent and interdisciplinary research center in Molecular Me-dicine, situated on the campus of the Medical University and the Ge-neral Hospital in Vienna. Driven by medical needs, CeMM integrates basic research and clinical experti-se to pursue innovative diagnostic
and therapeutic approaches. 13 groups with about 150 scientists focus on cancer, inflammation and immune disorders. CeMM aims to assist in preparing the predictive, preventive and personalized me-dicine of the future, and to train a new generation of researchers in molecular medicine.
Contact personStefan Kubicek,
Sebastian Nijman, Group Leaders at CeMM
CSC Pharmaceuticals
Booth 46Gewerbestraße 18-20
A-2102 BisambergT. +43 (0)2262 6060
F. +43 (0)2262 606 [email protected]
www.csc-pharma.at
CSC Pharmaceuticals, as part of the international Angelini group with 3.600 employees worldwide, operates regionally, mainly in Cen-tral & Eastern Europe. Our mission is to meet customers’ day-to-day needs with effective, reliable and high-quality pharmaceuticals. Our
product range grows continuously to encounter the emerging needs of hospital, Rx and OTC markets by focusing on four main therapeutic areas, which are: pain relief, neu-ropsychiatry, oral care, and gyne-cology.
Contact personDr. Gerda Achzet,Licensing Manager CEE
CeMM Reserach Center for Molecular MedicineBooth 45
Dutalys GmbH
Booth 46Muthgasse 11/2, 3.OG
A-1190 ViennaT. +43 (0)1 9971832
F. +43 (0)1 [email protected]
www.dutalys.com
17
Dutalys is a private, Austrian an-tibody technology company com-mitted to developing superior treatments for complex and mul-tifactorial diseases, including can-cers and inflammatory diseases. Dutalys has built the DutaMab™ platform technology to provide the only class of bispecific anti-
body molecules that retain all the advantages of state-of-the-art monospecific antibody therapeu-tics. The benefits of DutaMabs™ include high affinity against all classes of drug targets, convenient manufacturing fully equivalent to monospecific antibody drugs, and outstanding stability.
Contact personDr. Roland Beckmann, CSO
ecoplus. The Business Agency of Lower AustriaBooth 46
ecoplus, the business agency of Lo-wer Austria in the centre of Europe acts as interface between business and politics, companies and authori-ties, investors and initiators of regio-nal projects on both a national and international scale. ecoplus offers tailored services, information and support to companies, project ba-ckers and partners in areas such as:
• Establishment or expansion of companies; • Provision of attractive company locations; • Facilitation of access to educational and R&D facilities; • Intercompany cooperation and networks; • Initiatives involving market activities in the new Europe.
Magnesitstraße 1A-3500 KremsT. +43 (0)664 612 69 48F. +43 (0)2732 87470 [email protected] www.ecoplus.at
Contact personVerena Ossmann
Campus Vienna Biocenter IIViehmarktgasse 2a/2 OGA-1030 ViennaT. +43 (0)1 890 080 410 F. +43 (0)1 [email protected]
18
EUCODIS Bioscience is an applica-tion-driven enzyme engineering and manufacturing company. We offer high-performance enzymes for biopharma, fine chemicals, cosmetics industry: over 50 enzy-mes like betalactamases, lipases, catalases and others, which are selected to include the desired
properties, i.e. chiral and regiose-lectivity, broader temperature- and pH-profiles. We engineer enzymes according to our customers’ re-quirements, using our proprietary mutagenesis and recombination toolbox. We provide customized services in recombinant protein and enzyme production.
Contact personDr. Susanne Bach,
Key Account Manager
Evercyte GmbH
Booth 46Muthgasse 18, A-1190 Vienna
+43 (0)699 18162222 (scientific issues)+43 (0)664 4227861 (business issues)
[email protected]@evercyte.com
www.evercyte.com
Evercyte is a provider of relevant preclinical model systems that will allow for acceleration of drug discovery and development by re-duction of development time and cost. These cellular model sys-tems are based on primary cells that are immortalized without altering key functional characte-
ristics or by using adult stem cells and urine-derived, induced pluri-potent stem cells.Evercyte offers immortalized cell lines and panels of different tis-sues, cell culture media and the development of customer-tailored cell based assays and cells for pre-clinical target- and drug research.
Contact personOtto Kanzler, CEO and co-founderJohannes Grillari, CSO and co-founder
EUCODIS Bioscience GmbHBooth 46
F4 Pharma i.G.Booth 46
19
F4 Pharma i.G. is a development stage bio-pharmaceutical compa-ny established 2013 in Vienna. The core product is FX06 – a peptide with high potential in indications associated with vascular leakage. Development will be concentra-ted on two indications (1.) vaso-plegic syndrome – a certain form
of circulatory shock and (2.) kidney transplantation. Solid preclini-cal and clinical data are available and warrant a direct start in ph II. Human data from ph I and ph IIa studies proofed a favorable safety profile, excellent tolerability and transferability of results from ani-mal models to men.
Contact personDr. Petra Wülfroth, CEO (designated)
FFG – Austrian Research Promotion AgencyBooth 46
The Austrian Research Promoti-on Agency (FFG) is the national funding institution for applied re-search and development in Austria.We offer a comprehensive range of services for Austrian enterpri-ses, research institutions and re-searchers – from the management of public funding programmes to
consulting services in all phases of technology development and innovation, from support for in-tegration into European research programmes and networks to the promotion of Austria“s interests at the European and the interna-tional level.
Sensengasse 1A-1090 ViennaT. +43 (0)5 7755 0 F. +43 (0)5 7755 [email protected]
Contact personDr. Astrid Hoebertz,
Project Manager
Bürgerspitalgasse 24/10 A-1060 Vienna
T. +41 79 788 [email protected]
www.F4-Pharma.com
Helmut-Qualtinger-Gasse 2A-1030 ViennaT. +43 (0)1 6066877 3511F. +43 (0)1 6066877 [email protected]
20
The Division of Molecular Biotech-nology is part of the University of Applied Sciences, FH Campus Vi-enna. Our research activities cover two separate areas. In a focus on signaling pathways we generate reporter systems to study the cel-lular activities of the heat shock pathway and the Wnt pathway
for drug development. In a second focus on allergy research we deve-lop tools for improved diagnosis and treatment of food allergies. In addition, we investigate pathome-chanisms underlying respiratory allergies for identification thera-peutic targets.
Contact person Dr. Thomas Czerny,
Research Molecular Biotechnology
Greiner Bio One
Booth 46Gewerbepark 2
A-4261 RainbachT. +43 (0)664 88 41 06 75
A subsidiary of Greiner Bio-One – Lambda – is a biotech company that develops and produces mole-cular diagnostic solutions for the detection of pathogens (viruses and bacteria) from various speci-mens. Further fields of research and development include food di-agnostics and quality control pro-
ducts for the pharmaceutical in-dustry. With the novel GENSPEED® Test System we developed a mole-cular diagnostics platform that for the first time enables simple, rapid and simultaneous detection of up to 8 parameters from various spe-cimens.
Contact personDr. Max Sonnleitner, Business Development, Area Manager GENSPEED
FH Campus Vienna –University of Applied SciencesBooth 45
Haplogen GmbH
Booth 46Campus Vienna Biocenter 5
A-1030 ViennaT. +43 (0)1 916 55 22 10F. +43 (0)1 916 55 22 [email protected]
www.haplogen.com
21
Haplogen is a privately held bio-technology company based on an entirely novel genetics technology platform. Its goal is to combat in-fectious diseases.Despite improved hygiene and successful vaccination programs, infectious diseases remain a major cause of morbidity and mortality.
Emerging resistance to conventi-onal drugs and a lack of scientific tools further add to this immense medical and socio-economic pro-blem. Our mission is to identify novel pathogen host factors using our proprietary technology and thereby develop therapeutics to treat infectious diseases.
Contact personDr. Georg Casari, CEO
Health Technology ClusterBooth 46
The Health Technology Cluster is a network for increasing innovative capacity and international com-petitiveness of Health Technology companies, their suppliers as well as relevant research and health-care facilities. The cluster currently connects 220 partner companies from Austria and South Germa-
ny. Due to the Upper Austrian strength in medical technology, the main focus is on medical elec-tronics, software, clean room & hygiene, hospital equipment, end-user products, diagnostics-phar-ma and materials. More detailed information under www.gesund-heits-cluster.at
Hafenstraße 47-51A-4020 LinzT. +43 (0)732 79810 5151F. +43 (0)732 79810 [email protected]
Contact personDI (FH) Philipp Wittmann,
Cluster Manager
Helmut-Qualtinger-Gasse 2A-1030 ViennaT. +43 (0)1 890 63 60F. +43 (0)1 890 63 60 [email protected]
22
Hookipa Biotech develops a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® techno-logy, which is a novel vaccine plat-form using a replication-defective viral vector for the prevention and treatment of multiple infectious
diseases and cancer. The platform is one of the most promising new technologies for next generati-on vaccines due to its ability to stimulate both potent B-cell and CD8+ T-cell immune responses. Vaxwave® has been validated in various disease models.
Contact personDr. Katherine Cohen, CEO
Human.technology Styria GmbH
Booth 46Reininghausstraße 13
A-8020 GrazT. +43 (0)316 587016
F. +43 (0)316 587016 [email protected]
www.humantechnology.at
Human.technology Styria is a membership organization for life science & related industries in Aus-tria, a powerhouse of innovation in the following fields:• Biobanking and biomarker technologies• Process engineering for pharmaceutical and biotechnology companies
• Advanced biomedical sensor technologiesThe Cluster has assembled a highly integrated network of life science companies across Styria including start-ups right up to industry flag-ships. This hotbed of business de-velopment backed by world class science ensures that companies in Styria have that edge for success.
Contact personDr. Robert Gfrerer, CEO
Hookipa Biotech AGBooth 46
IMBA Institute of Molecular Biotechnology GmbH
Booth 45Dr. Bohr-Gasse 3
A-1030 ViennaT. +43 (0)1 79044 4400F. +43 (0)1 79044 4401
23
IMBA – Institute of Molecular Bio-technology is one of the leading biomedical research institutes in Europe focusing on cutting-edge functional genomics and stem cell technologies. The major research fields are: Disease modeling and mouse genetics, stem cell and RNA biology. IMBA is located at the Campus Vienna Biocenter,
the vibrant cluster of universities, research institutes, and biotech companies in Austria. With almost 200 employees and an annual re-search budget of around 25 milli-on, IMBA is the largest research unit of the Austrian Academy of Sciences, the leading national sponsor of non-university acade-mic research.
Contact personDipl. Kfm. Michael Krebs,Managing Director
in-spectumBooth 46
in-spectum e.U. offers Executive Search and Consulting Services. The expertise of in-spectum co-vers Direct Searches for national, regional and Headquarter func-tions such as General and Regional Manager roles, Head of Corporate Affairs, Regulatory Affairs, BD, IP, M&S, Medical, R&D, Operations,
Preclinical Facilities for Human and Animal Healthcare, Biotech-nology and Research Institutions. The services of in-spectum inclu-de Career Consulting and Syste-mic Coaching in German, English, French and Bulgarian language and focus on the individual needs of the Clients.
Kupelwiesergasse 5A-1130 ViennaT. +43 (0)664 1010079F. +43 (0)1 876 [email protected]
Contact personElisaweta Bubits, Owner
Graumanngasse 7/Stiege BA-1150 ViennaT. +43 (0)1 715 72 67 0F. +43 (0)1 715 72 67 [email protected]
24
INiTS is a business incubator desi-gned to improve the rate of star-tup success in Vienna by helping young entrepreneurs conceive, launch and grow the next great company. During our program, startups receive funding, hands-on support, resources, a network
and an office space to bring them to the next level.The program is aimed at bright and ambitious graduates, staff and students of the Vienna uni-versities and technical colleges with great ideas.
Contact personDr. Irene Fialka, CEO
Innovacell Biotechnologie AG
Booth 46Mitterweg 24
A-6020 InnsbruckT. +43 (0)512 573680
F. +43 (0)512 573680 [email protected]
www.innovacell.com
Innovacell Biotechnologie AG is a privately-held Phase III biotechno-logy company based in Innsbruck, Austria. The company is engaged in the clinical development and commercialization of autologous (i.e. patient’s own cells), minimally invasive cell therapies.
Innovacell’s personalized products are potentially curative one-off treatments, which re-establish functionality of sphincter muscles in patients, e.g. with stress urinary incontinence (SUI) or faecal incon-tinence (FI).
Contact personEkkehart Steinhuber, CEO
INiTS Universitäres Gründerservice Wien GmbHBooth 45
INOXIA Lifesciences GmbH
Booth 46Erlgasse 48
A-1120 ViennaT. +43 (0)1 810 53 66
F. +43 (0)1 810 53 66 [email protected]
www.inoxia.at
25
INOXIA is an innovative newly founded Viennese Biotech Com-pany which specializes in the field of drug development, with human peroxidases as the main target. Peroxidases are innate immune system enzymes, and are respon-sible for chronic inflammatory and neurodegenerative diseases.
Selective potential inhibitors form the basis for new medication, to be used for the treatment of Asthma, COPD, Endometriosis and bowel diseases such as Crohn s disease and Ulcerative colitis, to mention a few. The company is developing small molecule candidates for ent-ry into clinical trials.
Contact personDr. Andreas Kubin, CEO
Joanneum ResearchBooth 46
Our central activity is innovative applied research that bridges the gap between basic research and applications. Working according to high international quality stan-dards (GLP, EN ISO 13485), we are a valued partner for the pharmaceu-tical R&D and pharmaceutical and medical device industries. We of-fer services in these areas:
• Pharmacokinetics/pharma- codynamics / bioequivalence;• Biological and pharmaceutical analysis;• Metabolomics;• Health economics & outcome research;• Medical device development & evaluation.
Elisabethstrasse 5A-8010 GrazT. +43 (0)316 876 4000F. +43 (0)316 8769 [email protected]/health
Contact personDr. Frank Sinner,
Deputy Director of Institute
Lifesciences
Singerstrasse 8/9A-1010 ViennaT. +43 (0)1 512 77 91 F. +43 (0)1 512 47 [email protected]
26
We are a Patent Law Office with Headquarters in Vienna and Bran-ch Offices in Linz and Salzburg. Our office offers expertise in all techni-cal fields which enables us to pro-vide patent prosecution services with no restriction to our clients.
Additionally we are experienced in patent litigation matters not only in Austria but also with internati-onal orientation. Trademarks and Designs matters complete our services that we are able to offer to our clients.
Contact personDr. Andreas Pföstl,
Patent Attorney
Lacerta Technologies GmbH
Booth 46Dr. Karl-Dorrek-Str. 23-29
A-3500 Krems an der DonauT. +43 (0)664 883 16205
F. +43 (0)664 77 [email protected]
www.lacertatechnologies.com
Lacerta Technologies is a regene-rative medicine company located in Krems, Austria which targets to translate research results into products for clinical use. Lacerta aims to develop new solutions for patients who suffer bone loss by facilitating complete bone re-covery. To reach this goal Lacerta
is focusing on the development of a unique bone graft technolo-gy which is capable to accelerate bone healing as well as a custom-made bone graft system creating personalized bone graft coatings for specialized clinics and tissue banks.
Contact personZsombor Lacza, MD, PhD
Kliment & Henhapel Patentanwälte OGBooth 46
wien | linz | salzburg
Ludwig Boltzmann Gesellschaft
Booth 45Nußdorfer Straße 64
A-1090 ViennaT. +43 (0)1 513 27 50 29
F. +43 (0)1 513 23 [email protected]
www.lbg.ac.at
27
The Ludwig Boltzmann Gesell-schaft (LBG) is a non-university research organization based in Vi-enna, operating research institutes (Ludwig Boltzmann Institutes) in the fields of medicine / life sciences as well as the humanities, social-
and cultural sciences. The LBG in-itiates the collaboration between academic and company partners to pursue innovative translational research projects and to bridge the gap between basic research and application.
Contact personPeter Mayrhofer,Senior Manager Medical & Life SciencesUniv. Prof. DI Dr. Heinz Redl,Director Ludwig Boltzmann Institute for Experimental and Clinical Traumatology
LifeScience Vienna MuthgasseBooth 46
LifeScience Vienna MuthgasseVienna‘s new Innovation Center for Research & Teaching in the 19th district.Infrastructure requirements for different fields of research such as Biology, chemistry and physics – up to level S3. More than 21,000 square metres of office and lab space is already in use. (University
of Natural Resources and Life Sci-ences (BOKU), companies & orga-nisations)Next buildings:BioTech II28,900 m2 of flexible and state-of-the-art laboratories & offices. 203 parking spacesWhite Space25,355 m2 and 340 parking spaces
Weyringergasse 34/2A-1040 ViennaT. +43 (0)699 17131621F. +43 (0)1 3064306 [email protected]
Contact personMehrdokht Tesar,
PR & Marketing
Walcherstraße 11AA-1020 Vienna T. +43 (0)1 501 75 358 F. +43 (0)1 501 75 [email protected] www.LISAvienna.at
28
LISAvienna - Life Science Austria Vienna is the life science cluster organization of the City of Vienna, serving all stakeholders in the are-as of biotechnology/pharmaceuti-cals and medical technology.As a joint initiative of the Republic of Austria and the City of Vienna, LISAvienna helps to ensure that
the economic potential of life sciences is put to good use and turned into marketable products, improved processes and new ser-vices. The main focus of its activi-ties is on custom-tailored advice and assistance for innovative enterprises.
Contact personJürgen Fuchs,
Clustermanager Biotech/Pharma
Marinomed Biotechnologie GmbH
Booth 46Veterinärplatz 1
A-1210 ViennaT. +43 (0)1 25077 4460F. +43 (0)1 25077 4493
Marinomed Biotechnologie GmbH is a biopharmaceutical develop-ment company focusing on the development of innovative thera-pies against respiratory diseases (as common cold and influenza) based on an innovative anti-viral respiratory technology platform called mavirex. In addition, Mari-
nomed develops pharmaceuticals in type I allergy, and autoimmune diseases. Safety and effectiven-ess of the mavirex platform have been proven in three clinical trials in adults and children and by its marketed anti-viral OTC common cold and influenza portfolio.
Contact personMag. Johanna Uhlmann, Head Business Development
LISAviennaBooth 45,46
Matschnig & Forsthuber OGPatentanwaltskanzlei
Booth 46Siebensterngasse 54
A-1070 ViennaT. +43 (0)1 5233496F. +43 (0)1 5264886
29
Patentanwaltskanzlei Matschnig & Forsthuber has been operating for 30 years on a national and in-ternational level in all fields of in-tellectual property rights.The firm‘s services include professi-onal support and representation of patents, trademarks, designs and other industrial property rights as
well as consulting in all aspects of intellectual property. Our team of legally trained acade-mics with technical and scientific background covers a wide range of disciplines including physics, me-chanical engineering, electronics, telecommunications, chemistry and life sciences.
Contact personDr. Petra Gufler,European Patent Attorney
Medical University of GrazBooth 46
The core competencies of the Me-dical University of Graz are high standard education, research at an international level, and the continuous improvement of top-quality medicine.In the immediate vicinity of the university hospital the Center for Medical Research (ZMF) and the
large Biobank Graz offer ultra-modern infrastructure and know-how for projects with scientific and corporate partners. Commit-ted researchers from all areas of medicine perform high-ranking research and engage in coopera-tive research projects as well as significant clinical studies.
Auenbruggerplatz 2A-8036 GrazT. +43 (0)316 385 72018F. +43 (0)316 385 72030 [email protected]
Contact personDr. Heidi Schmitt,
Technology Transfer
Spitalgasse 23A-1090 ViennaT. +43 (0)1 40160 25203F. +43 (0)1 40160 [email protected]
30
The Medical University of Vienna (MedUni Vienna) is one of Europe’s medical training and research faci-lities with the greatest history and tradition. Counting almost 7,500 students, it is today the largest medical training facility in the German-speaking region. With
its 31 university departments, 12 medical-theoretical centres and numerous highly specialised la-boratories, it also ranks amongst the most significant cutting-edge research institutions in Europe in the biomedical sector.
Contact personDr. Claudia Ballaun, IPR Managerin
Univ.Doz. Dr. Andrea Kolbus, IPR Managerin
MucokineticaBooth 46
Schiffmühlenstrasse 47 / 330A-1220 Vienna
T. +44 (0)7774 [email protected]
www.mucokinetica.com
• Epithelial biology drug discovery & development company • Lead product is an Orphan Drug treatment for Cystic Fibrosis with enhanced pharmacological profile compared to existing treatments• Long duration reduction of
excessive sodium absorption in the airways; and long duration increased ciliary transport of secretions• PreSeed funding support from AWS• Seeking funding for pre-clinical and early clinical development
Contact personDr. Rod Hall, CEO and Chief Scientific Officer
Medical University of ViennaBooth 45
Nabriva Therapeutics AG
Booth 46Leberstrasse 20
A-1110 ViennaT. +43 (0)1 74093 1240
31
Nabriva specializes in developing pleuromutilins, a new class of an-tibiotics in humans, to treat seve-re bacterial infections, an unmet medical need. BC-3781, the lead product (Phase 3 ready), is a broad spectrum agent for treating com-plicated skin infections (cSSSI) and pneumonia caused by resistant
bacteria. Proof of concept for the systemic use in human was achie-ved in a Phase 2 trial in patients with cSSSI. BC-7013 is in Phase 1 de-velopment for topical treatment of bacterial infections.Pleuromutilins broadening Gram-negative coverage are the latest addition to the portfolio.
Contact personRalf Schmid, CEO
OncoQR ML OGBooth 46
OncoQR ML is a new Austrian bio-tech company founded 2012 by two seasoned pharma professio-nals, Dr. Geert Mudde and Christof Langer, MSc, MBA. OncoQR aims to develop, produce, and market biological drugs against oncolo-gical diseases. OncoQR’s fi rst pro-duct (OQR100) is directed against gastro-intestinal (pancreatic) cancer.
The drug concept is based on the potential of a proprietory S-TIR™ platform, which allows reversible treatment by either starving of tu-mor cells and/or tumor cell death due to cytotoxic T cells, CMC (complement mediated cytotoxi-city), and ADCC (antibody depen-dant cellular cytotoxicity).
Walterstrasse 21 A-3011 TullnerbachT. +43 (0)664 516 00 [email protected]
Contact personDI. Christof Langer, MBA, CEO
Leberstrasse 20A-1110 ViennaT. +43 (0)676 448 [email protected]
32
Origimm is a young ambitious Austrian biotech company striving to become a market leader in pro-tective antigen discovery. Using its proprietary ProVaDis® technology platform Origimm supplies its candidates to industry pipelines for innovative vaccine and immu-ne therapy development.
Origimm discovers most effective antigen candidates for the 1st pa-thogen specific therapeutic vacci-ne for treatment of acne vulgaris.Origimm is proactively looking for partnerships with academics and industry players to define and run further antigen discovery pro-grams on a demand driven way.
Contact personDr. Sanja Selak,
Founder and CSO
Ortner Reinraumtechnik GmbH
Booth 46Uferweg 7
A-9500 VillachT. +43 (0)4242 311 660
F. +43 (0)4242 311 660 [email protected]
www.ortner-group.com
As equipment and systems ma-nufacturer for cleanroom require-ments in the life science industry, the Ortner group offers a selected product range for creating clean-ness. The company has positioned
itself as a systems supplier for locks and decontamination pro-cesses. Accordingly, Ortner creates clean and high-quality production environments to ensure secure end products for their customers.
Contact personStefanie Rud, Vice President
Origimm e.U.Booth 46
Parkring 10A-1010 Vienna
T. +43 (0)664 8557369 [email protected]
www.panoptes-pharma.com
33
Panoptes is a privately held bio-tech company focusing on deve-loping small molecule therapies for the treatment of severe eye diseases with high unmet need. The development of clinical can-didate PP-001 focuses on autoim-mune uveitis. As a second indica-tion, adenoviral conjunctivitis will be pursued, a disease for which
to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications. We believe the combination of our technology and cost-efficient development strategy will help ensure a rapid and more predictable path to com-mercialization.
Contact personDr. Franz Obermayr, CEO
PDC Biotech GmbHBooth 46
PDC Biotech (PDC) is developing a proprietary series of prostaglan-din F2 receptor antagonists for the treatment of preterm labour and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. PDC has successfully completed the first-in-human clinical trial for its
lead compound PDC31. This study was designed to evaluate safety as well as provide proof of con-cept for the ability to inhibit ex-cessive uterine contractility. The company’s immediate goal is to continue development of its lead program to proof of concept in pregnant women.
Kaerntner Ring 10/12A-1010 ViennaT. +43 (0)1 890 0077 10F. +43 (0)1 890 3518 [email protected]
Contact personRoman Götz,
Managing Director
PanoptesPharma GmbH
Booth 46
Ferdinand-Pichler-Gasse 2A-2500 BadenT. +43 (0)664 5160842F. +43 (0)2252 [email protected]
34
Class-Leading Service Provider & CRO for Bioanalysis. GLP and GMP certi-fied, escorting clinical phases I-III, pre-clinical and early stage investigation. QUANTIFICATION: Assay develop-ment and validation for substan-ces in plasma / urine / tissue with extremely high sensitivity (e.g. 250 fg/mL plasma). IDENTIFICATION: Structure eluci-
dation of unknown peaks: Meta-bolite profiling, impurities, degra-dation productsINVESTIGATION• Bioanalytical feasibilities • Tissue analysis• Trouble shootingBIOMARKERS: Discovery of bio-markers in plasma: Small Molecu-les & Peptides, Several Patents
Contact personMartin van Dam,
Director Business Development
Polymun GmbHBooth 46
Donaustr. 99A-3400 Klosterneuburg
T. +43 (0)2243 25060 300F. +43 (0)2243 25060 399
Polymun is a privately held CMO near Vienna, Austria, founded in 1992. Our core activities are contract development and ma-nufacturing of biopharmaceuti-cals (mammalian and microbial expression systems) as well as liposomal formulations. Polymun operates in accordance with GMP guidelines and holds an Austrian
production license thus meeting all EU requirements for drug ma-nufacturing (last inspection June 2013).Polymun employs a team of more than 50 highly qualified scien-tists, technologists and support staff. We are a flexible partner focused on the requirements of our clients.
Contact personDr. Dietmar Katinger, CEO
pharm-analyt Labor GmbHBooth 46
QuintilesBooth 46Stella-Klein-Löw-Weg 15
A-1020 ViennaT. +43 (0)664 5337014
www.quintiles.com
35
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceu-tical development and commer-cial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commer-cialize all of the top-50 best-selling drugs on the market. Quintiles ap-plies the breadth and depth of our
service offerings along with ex-tensive therapeutic, scientific and analytics expertise to help our cus-tomers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Contact personDr. Nora Gedeon,Director Global Sales
Recardio GmbHBooth 46
RECARDIO (REgenerative CARDIO-vascular Therapy) is an innovative, Klagenfurt based life science com-pany founded in 2011. It is focusing on regenerative therapeutic mo-dalities for the treatment of car-diovascular diseases. After esta-blishing proof-of-principle in vivo
and the completion of its preclini-cal development, it is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiova-scular diseases, with the potential of improving their cardiac func-tion, quality of life and survival.
Lakeside B07bA-9020 KlagenfurtT. +43 (0)463 210 131F. +43 (0)463 210 [email protected]
Contact personDr. Roman Schenk, CEO
Donau-City-Straße 1A-1220 ViennaT. +43 (0)1 20501 47100 F. +43 (0)1 20501 [email protected]
36
The life science industry. Exciting ideas. Huge potential. You attract partners. Negotiate deals. Stay ahead of the competition. When it comes to patents, we mean business. REDL Life Science Patent Attorneys is an IP law firm with a team of specialists in the area of Life Science. At REDL Life Science Patent Attorneys, we are com-
mitted to protecting your most valuable assets. We obtain com-mercially valuable patents and other IP rights for your products and technologies. We assess the strength of patents during licen-sing or financing negotiations. We assert your rights in case of con-flicts. Our primary goal is to sup-port your business.
Contact personDr. Gerda Redl,
Patent and Trademark Attorney, European Patent Attorney
Dr. Manuela Loidl, European Patent Attorney
roombioticBooth 46
Petersgasse 12A-8010 Graz
T. +43 (0)316 873 8814F. +43 (0)316 873 8819
[email protected]://sciencepark.at/unsere-firmen/448/roombiotic
roombiotic is developing deconta-mination technologies based on airborne antimicrobial substances. These small molecules belong to secondary metabolites which are involved in the signal transduction of microorganisms. The company is specialized on the identification of novel antimicrobial substances
from natural occurring microbial antagonists. The main focus is a residue-free decontamination of complex surfaces and microstruc-tures with biogenic substances. This technology is suitable for use in the food industry to minimize the loss of quality along the value chain.
Contact personStefan Liebminger,Founder, R&D
REDL Life Science Patent AttorneysBooth 46
[roombiotic]probiotic solutions
S-TARget therapeutics GmbH
Booth 46Mooslackengasse 17
A-1190 ViennaT. +43 (0)69918904206
37
S-TARget therapeutics develops human specific therapeutic vac-cines to cure and prevent severe allergic diseases, based on the pro-prietary S-TIRtm technology plat-form. S-TARget’s therapies are not limited by the patient’s IgE levels.SG100, S-TARget‘s 1st clinical can-didate against house dust mite
(HDM) induced allergic asthma, re-cently achieved in vivo PoC in pha-se 1 and 2 like clinical studies with non human primates suffering from this disease. Both HDM indu-ced early and metacholin induced late phase reactions were signifi-cantly improved in treated animals versus placebo controls.
Contact personDr. Geert C. Mudde
Sandoz GmbHBooth 46
The Biopharmaceuticals unit at Sandoz GmbH, an international pharmaceutical company (2012 sales: US$ 8,7 bn), is focusing on biosimilar products as well as on biotech cooperations with Third Parties. Based on many years of experi-ence in recombinant microbial and mammalian cell culture produc-
tion at commercial scale, Sandoz is in the position to provide cGMP manufacture of products for clini-cal trials and commercial supply. Sandoz offers production of re-combinant proteins in 1,300L up to 40,000L fermenters comprising corresponding purification lines in multipurpose facilities in Austria.
Biochemiestrasse 10A-6250 KundlT. +43 (0)664 8271441F. + 43 (0)[email protected]
Contact personDr. Bernhard Siebold,
Manager Biotech Cooperations
Boltzmanngasse 11A-1090 ViennaT. +43 (0)1 319 14 56 324F. +43 (0)1 319 14 56 [email protected]
38
Sanochemia Pharmazeutika AG is an internationally active specialty pharmaceuticals company with a long track record in the develop-ment and production of human pharmaceuticals, diagnostics and veterinary drugs. The Company specializes in segments of the on-cology, neurodegeneration and,
in particular, imaging diagnostic markets. Currently the core focus is on the development of efficient cancer diagnostics such as Vidon®, a photodynamic diagnostic agent for improved detection of bladder cancer, and Secrelux®, a pancreatic function diagnostic agent.
Contact personDr. Klaus Gerdes, CMO/COO
Sanova PharmaBooth 46
Haidestrasse 4A-1110 Vienna
T. +43 (0)1 80104 2521F. +43 (0)1 80104 9382
[email protected] www.sanova.at
Sanova Pharma is the leading dis-tributor who cares for the marke-ting, sales and logistics of foreign companies’ products in Austria. Thus we make YOUR products a success!Sanova addresses both medical doctors and pharmacies. In the RX business we target GPs, gast-roenterologists, endocrinologists,
ENT doctors and other disciplines, depending from the current focus.In the OTC business leading pro-ducts in the field of cough & cold, gastro-intestinal disorders, nail fungus, etc. make us no. 2 in Austria.Come and talk to us, Sanova will be happy to sell your products in Austria.
Contact personAlexander Burstein,Director Business Development
Sanochemia Pharmazeutika AGBooth 46
Savira pharmaceuticals GmbH
Booth 46Veterinärplatz 1, Building IA
A-1210 ViennaT. +43 (0)1 25077 5904F. +43 (0)1 25077 5999
39
Savira focuses on next generation influenza therapeutics. Our main project is the rational, structure-based design of inhibitors impe-ding the cap-snatching mecha-nism of the influenza polymerase eventually preventing the virus from hijacking the protein-produc-tion machinery of the infected cell.
2012 Savira signed an exclusive license and collaboration agree-ment with Roche. Savira and Ro-che have formed a strong and ef-fective R&D team, further backed by renowned scientists from the EMBL – one of Savira’s main share-holders.
Contact personDr. Oliver Szolar, CEO
Standortagentur TirolBooth 46
Part of the “Standortagentur Tirol”, the cluster management platform brings together top-class Tirolean research institu-tions from the life sciences sector with active companies located in the region. It imparts expertise, provides thematic impetus, offers links to specialist partners, en-
courages and supports interdis-ciplinary collaborations and R&D partnerships, thereby boosting innovation performance in the region and promoting enhanced competitiveness for both compa-nies and the region. The Cluster is co-financed by the European Re-gional Development Fund (ERDF).
Ing.-Etzel-Straße 17A-6020 InnsbruckT. +43 (0)512 576262-48F. +43 (0)512 [email protected] www.standort-tirol.at
Contact personDDR. Petra Stöckl,
Clustermanager Life Sience Tirol
Niederösterreichring 2, Haus BA-3100 St. PöltenT. +43 (0)2742 9000 19300F. +43 (0)2742 9000 [email protected]
40
tecnet equity is an agency of Lo-wer Austria with the mission to commercialise inventions and new technologies. tecnet is part-ner of premier universities and research organisations of Aust-ria moving their research results from the lab to the market and by
that transferring inventions into successful innovations. For our industry partners we enable fast and pragmatic collaborations with academic R&D and provide access to the latest technologies and pa-tents. tecnet also manages a ven-ture capital fund for start-ups.
Contact personMag. Lukas Madl,
Technology Transfer Manager
Themis Bioscience GmbH
Booth 46Muthgasse 11
A-1190 ViennaT. +43 (0)1 236 71 51
F. +43 (0)1 236 71 51 [email protected]
Themis Bioscience GmbH deve-lops vaccines against infectious diseases. The company focuses on emerging tropical infectious di-seases and develops vaccines from the preclinical to the early clinical phase. Initial vaccine candidates are currently being developed against Dengue and Chikungunya, with vaccines against other di-
seases a future possibility. The company’s own Themaxyn tech-nology platform, which has been licensed by the internationally respected Pasteur Institute in Pa-ris, forms the basis for all vaccine candidates of the Vienna-based company. This platform is highly innovative and fully protected by patents.
Contact personDr. Erich Tauber, CEO
tecnet equity GmbHBooth 46
Tikopia Consulting
Suedtirolergasse 17–21/5A-3423 St. Andrae-Woerdern
T. +43 (0)660 [email protected]
www.tikopia-consult.at
41
Tikopia Consulting is a consulting company specialized in project and quality management for the pharmaceutical, biotechnology, medical device, and related indus-try. Our services include Develop-mental Project Setup and Leader-ship, International Team Building, Business Development, Preclinical
and Toxicological Consultancy, Quality Management Systems and GMP Audits. We foster a result oriented working style, based on our long experience in the phar-maceutical industry. Customized solutions in close collaboration with our clients are the foundati-on of our success.
Contact personTheodor Langer, CEO
Tissue Med BiosciencesBooth 46
Tissue Med Biosciences is an Aus-trian biotech company develo-ping novel therapies for chronic diseases.The lead compound (TMBP-3) is a human recombinant protein for diabetic foot ulcer (DFU), a seri-ous consequence of diabetes type 2. Other proteins in development target indications in the field he-
matology and musculoskeletal diseases.A clinical phase 1 of TMBP-3 will be initiated in late 2013. TMBP-3 acts not only on skin cells but also on endothelial and immune cells. Therefore, the use is not restric-ted to DFU, but to patients with decubitus or venous ulcers and other severe wounds.
Magnesitstrasse 1A-3500 KremsT. +43 (0)2732 87470 310 [email protected]
Contact personDr. Rudolf Berger,CEO and Founder
6Booth 4
Leberstr. 20A-1110 ViennaT. +43 (0) 1 740935 100F. +43 (0) 1 740935 [email protected]
42
Tube is focusing on the develop-ment of small molecules derived from natural products for targe-ting approaches by using its prop-rietary toxin platforms Tubulysins (Cytolysins) and Epothilones as conjugation payloads for safer and more efficacious therapies. Tube’s own development product is a na-nopharmaceutical using a potent
tubulysin which shows an excel-lent efficacy and safety profile in many in-vivo studies. Tube is also involved in the co-development of other conjugation programs using peptides, proteins or antibodies as targeting principle. In addition, Tube offers synthesis services of complex organic molecules.
Contact personDr. Wolfgang Richter,
Managing Director
ugichem GmbH
Booth 46Mitterweg 24
A-6020 InnsbruckT. +43 (0)512 282285 10F. +43 (0)512 282285 11
Based on the innovative Ugimer® platform ugichem is developing innovative antisense therapeutics with a unique therapeutic efficacy profile for immune mediated in-
flammatory diseases (IMID) where existing therapies are insufficient or do not work. ugichem initially focuses on rheumatoid arthritis (RA) as lead indication.
Contact personDr. Holger Bock, CEO
Tube Pharmaceuticals GmbHBooth 46
University of TechnologyVienna
Booth 45Favoritenstrasse 16
A-1040 ViennaT. +43 (0)1 588014 15243F. +43 (0)1 588014 15980
43
The Vienna University of Technolo-gy (TU Vienna) is among the most successful technical universities in Europe and is Austria‘s largest sci-entific-technical research and edu-cational institution. Research areas cover all classic engineering dis-ciplines; many of them are highly
relevant for biotech and medtech industries. TU Vienna for examp-le hosts expertise in bioanalytics and sensor development, biome-chanics, biomedical engineering, chemical technologies, electro-dynamics, material sciences and software development.
Contact personDr. Hildegard Sieberth,Patentmanager
University of Veterinary Medicine ViennaBooth 45
The University of Veterinary Me-dicine Vienna is the only acade-mic, educational and research institution of veterinary medicine in Austria. Its animal hospital wel-comes patients 24/7. It is commit-ted to combine basic and applied clinical research of the highest quality, to meet the challenges of animal health and food safety.
The main areas of research are:• Physiological processes Infection and prevention, with a focus on farm animals;• Animal models and veterinary biotechnology;• Food safety and risk analysis;• Animal behaviour and human-animal interactions.
Veterinaerplatz 1A-1210 ViennaT. +43 (0)1 25077 1047F. +43 (0)1 25077 [email protected]; www.vetwidi.at
Contact personMag. Christine Ruckenbauer,Head of Technology Transfer
University of Vienna Research Services Berggasse 7, 2nd floorA-1090 ViennaT. +43 (0)1 4277 18222 [email protected]://forschung.univie.ac.at/en/technology-transfer/
44
The University of Vienna was esta-blished in 1365, and is currently one of the largest Universities in Cen-tral Europe. More than 400 aca-demic staff members are actively engaged in cutting-edge research in the biological and pharmaceuti-cal sciences in the Faculties of Life
Sciences and Chemistry, and at the Max F. Perutz Laboratories. The University of Vienna prides itself on its role as a leading provider of education and innovation in fun-damental and applied biological research in Austria.
Contact personDr. Ingrid Kelly,
Technology Transfer Manager
Valneva Austria GmbH
Booth 46Campus-Vienna-Biocenter 3
A-1030-ViennaT. +43 (0)1 206201125
F. +43 (0)1 [email protected]
www.valneva.com
Valneva is a new European biotech company focusing on antibody discovery and vaccine develop-ment and commercialization. It was created in 2013 through the merger between Intercell AG and Vivalis SA. Valneva generates di-versified revenue from both its
marketed Japanese encephalitis vaccine (IXIARO®), commercial part-nerships around a portfolio of product candidates (in-house and partnered) and licensed techno-logies (EB66 cell-line, VivaScreen antibody discovery, vaccine adju-vant IC31).
Contact personFrédéric Legros,Head of Business Development
University of ViennaBooth 45
Vela Laboratories GmbH
Booth 46Brunner Straße 69/6
A-1230 ViennaT. +43 (0)1 890597911F. +43 (0)1 890597910
45
Vela Laboratories is a world-wide acting, GMP-certified contract laboratory which offers in-depth analytical characterization ser-vices for proteins and peptides. Vela’s philosophy is to interact in-dividually with each of our clients. Together we are working out the analytical approach dedicated to meet all regulatory requirements
in accordance with the relevant guidelines. A key expertise of Vela is performing the comparability exercise for Biosimilars like growth factors and monoclonal antibo-dies. Within this portfolio, also cell-culture-based potency assay, e.g. CDC, ADCC and (anti)-prolife-ration have been established.
Contact personDr. Markus Fido, CEODr. Andreas Nechansky, COO
Vienna Business AgencyBooth 46
Vienna Business Agency – Your Start in ViennaWe are the first point of contact for national and international companies and investors who are looking to establish a branch in Vienna. As Vienna’s official investment promotion agency, we provide
you with comprehensive infor-mation about the business loca-tion Vienna, including tailor-ma-de support services, funding and real estate – no matter if you are a start-up or a multinational com-pany. All of our services are free of charge. Visit us online: www.vba.at
Schmerlingplatz 3A-1010 ViennaT. +43 (0)1 4000 86949 [email protected]
Donau-City-Strasse 1A-1220 ViennaT. +49 (0) 174 319 1173F. +43 (0)1 269912 [email protected]
46
ViruSure GmbH is a privately ow-ned GMP/GLP certified biotech company based in Vienna spe-cialising in virus and prion safe-ty testing of biopharmaceutical products. We offer client focused contract testing services with an expertise ensuring to meet au-thorities requirements worldwi-
de. Both our in vivo and in vitro testing facilities operate under a state of the art risk based quality management system. The services include: Virus- and Prion Removal Studies, Cell Banking, Cell Line Characterization, Potency Testing, Vaccine Testing, Tumorigenicity and Oncogenocity Studies.
Contact personDr. Ralf Klein,
Manager Business Development
VTU Technology GmbH
Booth 46Parkring 18
A-8074 GrambachT. +43 (0)316 4009 4000F. +43 (0)316 4009 4010
VTU Technology is a leading con-tract research and development company providing services for the fast track generation of high performance, industrial protein production strains and economi-cally viable protein production processes from lab to pilot sca-le. Based on its powerful Pichia pastoris expression platform VTU
offers time-saving development of cost-efficient recombinant pro-tein production processes yielding up to 20 g/L of secreted protein for serum proteins, cytokines, Fabs, antibody derived fragments, (HSA&Fc)fusion proteins, scaf-folds, vaccines and enzymes.
Contact personDr. Thomas Purkarthofer,Head Business Development
ViruSure GmbHBooth 46
Willheim Müller Rechtsanwälte
Booth 46Rockhgasse 6
A-1010 ViennaT. +43 (0)1 535 8008 0
F. +43 (0)1 535 8008 [email protected]
www.wmlaw.at
47
Willheim Müller Rechtsanwälte is an independent full service busi-ness law office located in Vienna, Austria. We work for global corpo-rations as well as small and medi-um sized companies, trusts, non-profit organisations, family offices as well as wealthy individuals. Our practice is business and sector ori-ented and expands across borders.
Major practice areas of WMLaw:• International Arbitration and Business Litigation• Corporate and M&A• Austrian and EU Competition and Antitrust Law• Foundations and Trusts• Infrastructure Projects (PPP-Proj.)• Real Estate• IP and IT- Law
Xiber Science GmbHBooth 46
Xiber develops first-in-class pepti-de drugs that prevent organ dama-ge. Xiber’s drugs have the potential to improve survival and outcome of critical care and transplant pa-tients, to reduce the duration of stay at the critical care unit and to alleviate life supportive measures. Initially Xiber will concentrate on following niche indications: Acute
Lung Injury & Primary Graft Dys-function after Lung Transplantati-on and prevention of Generalized Edema & Organ Failure in Severe Burn Victims. In a midterm per-spective Xiber aims to develop a prophylactic treatment to prevent organ failure in critical care and transplant patients.
Josefigasse 24A-2353 GuntramsdorfT. +43 (0)699 [email protected]
Contact personDr. Stephan Winklbauer, Partner
Contact personDr. Sonja Reingruber
Zetaplatz 1A-8501 Lieboch/GrazT. +43 (3136) 9010 0F. +43 (3136) 9010 [email protected]
48
Zeta is specialised in designing, engineering, development, ma-nufacture, automation and main-tenance of customised process solutions for aseptic applications.As a recognised technology sup-plier and R&D partner of the biotechnological and pharmaceu-tical industry, Zeta has compre-hensive competence, experience
and references in:• Up- and downstream systems• Preparation and formulation systems• CIP/SIP- and media systems• Sterile plant installation• Magnetic agitators• Freeze & thaw systems• Automation solutions
Contact personDr. Andreas Marchler,
Managing Director
ZIT – The Technology Agency of the City of Vienna
Booth 46Ebendorferstrasse 4
A-1010 ViennaT. +43 (0)1 4000 86178
ZIT serves as the technology promotion agency of the City of Vienna. The activities of ZIT encompass providing direct financial assis-tance (i.e. grants) to companies
or making a technology-specific infrastructure available, as well as the implementation of a broad range of accompanying measures in all phases of the innovation process.
Contact personPeter Halwachs, Consultant
Zeta Biopharma GmbHBooth 46
49
PARTNERING FOR INNOVATION
EUROMEDTECH™
2014
6th Annual International Medtech Partnering Conference
© 20
13 E
BD G
mbH
Linz i
mage
: www
.wer
befot
ogra
fi e.at
Apply to present now! Deadline: March 7, 2014
Find out more at www.ebdgroup.com/emt
MAY 7–8, 2014LINZ, AUSTRIADESIGN CENTER LINZ
GET YOUR MEDTECH DEALS DONE AT EUROMEDTECH™ 2014!Optimize your time, make your networking more effi cient, and connect directly with high level executives at EuroMedtech™ 2014 in Linz, Austria.
Producer Hosts
Featuring:� The user-friendly, industry-specifi c connection tool,
partneringONE®, that takes the guesswork out of event networking
� Company presentations and exhibits� Panels and workshops that explore the practices of
successful companies and the hot technologies that will lead dealmaking activity in the future
� Evening events at unique venues creating additional informal networking opportunities
Make the connections that matter:� Explore partnerships with small companies and
large corporations� Find suppliers or development partners� Reach out to investors� Connect with distributors, manufacturers and
consultants� Identify the right collaborators to get your products
to market
50
Austria at BIO-Europe 2013 Schedule
Topic: Service/CMO Tuesday, 5.11. Schubert 1
ACIB GmbH - Austrian Centre of Industrial Biotechnology
09:00
Topic: Vaccines Tuesday, 5.11. Schubert 4
Valneva Austria GmbH 11:00
AFFiRiS AG 11:30
Topic: Respiratory Tuesday, 5.11. Schubert 4
APEPTICO 14:15
S-TARget therapeutics GmbH 15:00
Topic: Cancer Tuesday, 5.11. Schubert 2
Apeiron Biologics AG 15:00
Activartis Biotech GmbH 16:15
Topic: Infectious Disease Wednesday, 6.11. Schubert 4
Haplogen 09:15
Marinomed Biotechnologie GmbH 09:45
Company Presentations by Topic
51
Monday, 4.11. Tuesday, 5.11. Wednesday, 6.11.
09:00 – 10:30WorkshopCollaborative approaches to translational research: Bridging the gap from target to leadRoom: Schubert 1
09:50 – 11:40Academic Innovators™ ShowcaseRoom: Schubert 5
09:45 – 10:30press conferenceBooth #46
10:45 – 11:15Welcome and Opening RemarksRoom: Strauss 1/2
14:00 – 16:00Next Generation Company Presentations Room: Schubert 5
14:45 – 15:45Panel DiscussionPublic funding in drug development: Analyzing the dose-effect relationshipRoom: Stolz 2
16:00 – 17:00International SeminarProduction and Platform TechnologiesRoom: Schubert 4
17:45 – 18:45Exhibit Hall Reception"Wiener Würstlstand"Booth # 46
18:00 – 22:00aws ReceptionCourtyard by Marriott Messe Wien
19:00 – 22:30Evening Networking ReceptionTown Hall
19:00 – 22:30Evening Networking Reception Metastadt
Time Company14:00 OncoQR OG14:10 Arsanis Biosciences
GmbH14:20 BDS Pharma GmbH14:30 Dutalys14:40 Evercyte GmbH14:50 Hookipa Biotech AG15:00 INOXIA Lifesciences
GmbH15:10 Akron Molecules
GmbH15:20 Origimm e.U.15:30 Panoptes Pharma15:40 roombiotic15:50 Xiber Science GmbH
OrganisationCeMM – Research Center for Molecular Medicine of the Austrian Academy of SciencesMedical University of ViennaUniversity of Vienna
aws Temporary Management
Financing of complementarymanagement expertisewww.awsg.at/maz
aws PreSeed
Financing the pre-start phasewww.preseed.at
aws Seedfinancing
Financing the start-up phase of life science companieswww.seed�nancing.at
We bringLife Sciences
to Life
50.000 Euro
200.000 Euro
1.000.000 Euro
www.lifescienceaustria.at
Austria Wirtschaftsservice GmbHWalcherstraße 11AA-1020 ViennaT. +43 (0)1 501 [email protected]
